BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Said vs. Filed

Harrow’s Ledger: Revenue Held, Profits Didn’t

Moe Alsumidaie by Moe Alsumidaie
November 11, 2026
in Said vs. Filed
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

The quick read

Harrow’s management spent most of 2026 promising both strong revenue and strong profits. The filed numbers show they delivered on one and badly missed the other. Revenue is on track; the EBITDA guidance was cut by more than half. That gap, between what was said on calls and what landed in filings, is the story.

Two numbers that should not coexist

On November 9, 2026, Harrow confirmed full-year revenue guidance of $350 million to $365 million, unchanged from the target it set at the start of the year. On the same day, it cut its full-year Adjusted EBITDA guidance, a measure of operating cash earnings before interest, taxes, and accounting charges, from a range of $80 million to $100 million down to “more than $40 million.” Same revenue, half the profit. A business can hold its top line and still bleed badly below it, and that is exactly what the November 9 8-K filing shows happened here.

Harrow started life as Imprimis Pharmaceuticals, a compounding pharmacy that mixed custom drug formulations for patients whose needs the branded market couldn’t meet. Over the past three years it has been remaking itself into a branded ophthalmic drug company, betting that products like VEVYE (a dry-eye treatment) and TRIESENCE (an eye injection) could carry margins that compounding never could. The pivot has driven revenue from a modest base in FY2023 to a projected $350-plus million this year. The question the filings now raise is whether the cost of that transformation was ever honestly priced into the guidance.

Claim one: “We will deliver $80 million to $100 million in Adjusted EBITDA”

This was the profitability promise Harrow carried into 2026. The filed record votes against it decisively. The company’s own letter to stockholders dated November 9 described first-half 2026 revenue as a meaningful miss against the implied guidance range. The shortfall traced directly to VEVYE, where management had built the guidance on assumptions about how much of the list price the company would actually collect after rebates and discounts, what the industry calls gross-to-net dynamics. Those assumptions were too optimistic, and the gap between the price on the label and the cash that arrived was wider than the model predicted.

BullScope TerminalHarrow was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

The cost side compounded the problem. Harrow accelerated spending on its G-MELT NDA submission, an application to bring a new sedation drug to market, added TYRVAYA integration costs after completing that acquisition in early October, and restructured its commercial organization into four specialized teams. Expenses grew faster than the plan assumed. The result: a profitability target that started near the top of its promised range ended the year guided at just over $40 million. That is not a rounding error. It is a rewrite.

The gap between the promised and the filed profit is the most load-bearing fact on the ledger for any analysis of whether Harrow’s improving revenue story translates into a business that earns its keep.

Claim two: “Revenue guidance stands at $350 million to $365 million”

Here the filed record largely agrees with management. The Q3 2026 10-Q shows quarterly revenue up nearly forty percent from the same quarter a year earlier, with branded revenue driven by record quarters for both VEVYE and TRIESENCE. IHEEZO unit demand grew meaningfully year over year. To hit the full-year target, Harrow needs a strong fourth quarter, and management has guided Q4 Adjusted EBITDA alone at more than $33 million, implying a sharp acceleration in the final stretch.

The revenue claim holds, at least through September. The compounding segment, Harrow’s original business, continued to shrink as branded products took a larger share of the mix. That shift is by design, and a gross margin of roughly three-quarters of every revenue dollar, stable against prior periods, suggests the branded products do carry the economics management promised. The revenue story is real. The profit story is where the ledger cracks.

Claim three: The guidance “deserves skepticism”

That phrase belongs to M. V. Cunha, writing on Substack after Harrow’s Q1 2026 earnings review, who noted a meaningful shortfall in implied first-half revenue against the original guidance and argued the reiterated full-year target warranted doubt. CEO Mark L. Baum reaffirmed the revenue range through the Q2 call in August 2026, and the Q3 numbers have since made the revenue case look more credible. But the EBITDA collapse gives the skeptic’s argument a second life: the revenue guidance held, yet the profit guidance was cut by more than half. Holding the top line while the bottom falls away is a particular kind of miss, one that is easy to obscure behind a headline number.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: Harrow and 500+ other names, on the same official data.See the evidence engine →

Zacks Research, cited by MarketBeat on November 9, moved its rating to the most cautious end of its scale before the Q3 results landed, citing concern that the profitability story had already broken down. The Q3 beat on revenue and GAAP earnings did not alter that published assessment within the filing window we can observe. Readers can weigh that external view alongside the filed numbers.

What the stock is pricing

Our data shows Harrow trading at a price-to-sales multiple well below its own decade median, placing it near the bottom of its own valuation history. The stock is down roughly half from its 52-week high. The mood, meaning what the market is currently paying, sits well below the math implied by the company’s historical trading range. Whether that discount reflects rational skepticism about the EBITDA miss or an overreaction to a revenue story that is still intact is the question the filed numbers alone cannot answer.

What the filings can say: Harrow has moved from deep losses in FY2023 to near breakeven in FY2025, and posted its first GAAP quarterly net income in Q3 2026, though that figure included a meaningful litigation settlement gain. The trajectory is real. Both facts belong in the same analytical frame: the trajectory is real, and so is the gap between that trajectory and the specific promises made on calls.

Reading the numbers

  • $99.3 million, Q3 2026 revenue. What it is: total sales for the three months ended September 30, 2026, per the Q3 10-Q. What it means: Harrow is now earning in a single quarter what it earned in all of FY2020. Worked example: a business that billed roughly $1 million a week three years ago is now billing roughly $7.5 million a week.
  • $114.9 million, first-half 2026 revenue. What it is: the sum of Q1 and Q2 2026 revenue, acknowledged as a miss in the stockholder letter. What it means: against guidance of $133 million to $153 million, the company delivered about 80 cents of every promised dollar. Worked example: a contractor who quoted $140,000 for a job and invoiced $115,000 by the halfway mark.
  • $40 million versus $80 million to $100 million, EBITDA guidance revision. What it is: the before-and-after on Harrow’s full-year profitability promise, per the November 9 8-K. What it means: the midpoint of the original range was $90 million; the new floor is $40 million. Worked example: a household that budgeted $9,000 in savings for the year and now expects to save $4,000, while spending the same amount on groceries as planned.
  • 75%, gross margin, Q3 2026. What it is: of every dollar Harrow collected in sales, 75 cents remained after paying for the drugs themselves and direct production costs. What it means: the branded product economics are working at the product level. The problem is what happens to those 75 cents further down the income statement, in selling, development, and administrative costs.
  • 3.6 times price-to-sales, versus a decade median of 6.3 times. What it is: the price tag the market puts on each dollar of Harrow’s annual sales, per our data. What it means: the stock is priced at roughly half its own historical norm. Worked example: a rental property that historically sold for six times annual rent is now changing hands at three and a half times, either because buyers see new risks or because they have overcorrected.

For the standing yardsticks on Harrow: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Harrow.

Sources

  • Harrow 10-Q, quarter ended September 30, 2026 (SEC EDGAR)
  • Harrow 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
  • Harrow 10-K, fiscal year ended December 31, 2023 (SEC EDGAR)
  • Harrow 8-K, November 9, 2026, EBITDA guidance revision (StockTitan)
  • Harrow Q3 2026 letter to stockholders (MarketScreener)
  • Harrow Q3 2026 financial results press release (GlobeNewswire)
  • M. V. Cunha, Harrow Q1 2026 earnings review (Substack)
  • Harrow Q3 2026 earnings summary including Zacks rating change (MarketBeat)
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read Harrow’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

CorMedix’s Reimbursement Cliff Meets a $145 Million Bet: What the Call Said, What the Filing Confirmed

by Moe Alsumidaie
November 16, 2026
0

An analyst asked the question that was sitting in every listener's mind. On the Q3 2026 earnings call on November 12, with revenue having fallen nearly in half...

Read moreDetails

The Quarter That Held Up, and the One Claim That Didn’t

by Moe Alsumidaie
November 6, 2026
0

Adaptive Biotechnologies spent six years losing money at a scale that would make most companies flinch. Then, on November 4, 2026, CEO Chad Robins called Q3 a "breakthrough...

Read moreDetails

CorMedix’s Scorecard: What Management Said, What the Filings Show, and Where the Story Gets Complicated

by Moe Alsumidaie
November 16, 2026
0

The quick read CorMedix spent years burning cash without a dollar of product revenue. Then DefenCath launched, and the filed numbers flipped almost overnight: the fiscal year 2025...

Read moreDetails

Lilly’s Ledger: The $4.2 Billion Footnote Management Hopes You Miss

by Moe Alsumidaie
October 30, 2026
0

A single acquisition charge, large enough to cut the company's earnings-per-share guidance even as management celebrated a revenue raise that left Wall Street cheering. That is what Eli...

Read moreDetails

Abbott’s Scorecard: What the Call Promised, What the Filings Show, and Where the Gap Lives

by Moe Alsumidaie
October 22, 2026
0

On the morning of October 21, 2026, Abbott's chief executive stepped onto a call with analysts and described a company growing in every direction. Four business segments, all...

Read moreDetails
Next Post

Merck Is Spending Like It Has a Problem. The Filed Numbers Say It Does.

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Novavax: A Company That Just Turned Profitable Is Priced Like It Might Not Survive

September 16, 2026

Receipts: Who Spends the Most Inventing Drugs?

September 1, 2026

NVIDIA Secures 4.25 IT-GW Ohio Data Center Capacity and Invests $1.5B in SB Energy to Lock in AI Infrastructure

August 19, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.